Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images) The stock price of Moderna saw a 12% jump on ...

Moderna’s current price is less than $20 below the psychologically significant $50 price level. Traders often focus on these ...

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading ...

President Joe Biden's outgoing administration on Thursday announced $211 million in new funding to develop mRNA vaccines ...

A statewide grand jury didn’t find evidence that COVID-19 vaccine manufacturers broke federal or state laws when making and ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

With a state grand jury report released Wednesday, Florida Gov. Ron DeSantis doubled down on the message he delivered often ...